AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16062095 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day and 100 mg/day
Number of subjects: 66
Study 12185154 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based care
Number of subjects: 201
Study 12185154 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 201
Study 10420140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate
Number of subjects: 76
Study 10420140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate
Number of subjects: 76
Study 10420140 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 76
Study 10420140 — intervention group
Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 76
Study 7486183 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (3.0 mg/kg)
Number of subjects: 41
Study 7486183 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (7.3 mg/kg)
Number of subjects: 41
Study 7486183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 1968484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (500 mg in 250 ml of 0.9% saline prior to catheter insertion and another 500 mg infused via the established catheter)
Number of subjects: 98
Study 1968484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline alone, same regimen as vancomycin)
Number of subjects: 98
Study 1968484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 98
Study 1968484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 30052571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation (10 billion colony-forming units daily for 6 months)
Number of subjects: 184
Study 30052571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LGG supplementation)
Number of subjects: 184
Study 30052571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation
Number of subjects: 184
Study 30052571 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 28739766 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stent implantation combined with intraluminal brachytherapy by 125I seeds articles
Number of subjects: 50
Study 28739766 — intervention group
Group type: COMPARATOR
Intervention: Biliary stent implantation only
Number of subjects: 50
Study 25307622 — intervention group
Group type: EXPERIMENTAL
Intervention: Local echocardiographic measurements of fractional shortening (FS)
Number of subjects: 59
Study 25307622 — intervention group
Group type: COMPARATOR
Intervention: Central echocardiographic measurements of fractional shortening (FS)
Number of subjects: 59
Study 25307622 — intervention group
Group type: EXPERIMENTAL
Intervention: Local categorization of LV function
Number of subjects: 59
Study 23161902 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg every 4 weeks (q4wks)
Number of subjects: 0
Study 23161902 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 4 weeks (q4wks)
Number of subjects: 0
Study 23161902 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg or 100 mg (from week 24)
Number of subjects: 0
Study 23161902 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg or 100 mg)
Number of subjects: 0
Study 23161902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21606190 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IA)
Number of subjects: 13
Study 21606190 — intervention group
Group type: COMPARATOR
Intervention: Regular Human Insulin (HI)
Number of subjects: 13
Study 21050483 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Fun program (teacher delivered universal program incorporating animal actions)
Number of subjects: 520
Study 21050483 — intervention group
Group type: COMPARATOR
Intervention: Control schools (six control schools)
Number of subjects: 520
Study 17169543 — intervention group
Group type: EXPERIMENTAL
Intervention: Kytta-Salbe f (comfrey root extract ointment), 6g daily application (3 x 2g) for 3 weeks
Number of subjects: 220
Study 17169543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 17169543 — intervention group
Group type: EXPERIMENTAL
Intervention: Kytta-Salbe f (comfrey root extract ointment)
Number of subjects: 220
Study 14741065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (Group R)
Number of subjects: 62
Study 14741065 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (Group B)
Number of subjects: 62
Study 12185118 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a facemask during cataract surgery
Number of subjects: 221
Study 12185118 — intervention group
Group type: COMPARATOR
Intervention: Not wearing a facemask during cataract surgery
Number of subjects: 221
Study 9748710 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release enteric-coated test formulation containing aesculus extract, 50 mg escin b.i.d.
Number of subjects: 18
Study 9748710 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release reference preparation, 50 mg escin b.i.d.
Number of subjects: 18
Study 7661265 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout with lactated Ringer's solution
Number of subjects: 23
Study 2501877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Ftorafur + Orimeten
Number of subjects: 16
Study 2501877 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide + Ftorafur + placebo
Number of subjects: 16
Study 351814 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 0.5% with epinephrine 1:200,000
Number of subjects: 48
Study 351814 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% with epinephrine 1:200,000
Number of subjects: 48
Study 351814 — intervention group
Group type: COMPARATOR
Intervention: Etidocaine 0.5% plain
Number of subjects: 48
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Current regular drinking (at least weekly)
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Current regular drinking in urban areas
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Current regular drinking in rural areas
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Current regular drinking at resurvey
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-regular drinkers
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking (> 60 g/session)
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking in rural areas
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking in urban areas
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking episodes among younger men (born in the 1970s)
Number of subjects: 512000
Study 30786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related risk factors among heavy drinkers
Number of subjects: 512000
Study 28928190 — intervention group
Group type: EXPERIMENTAL
Intervention: RADICALS (interdisciplinary model of care)
Number of subjects: 280
Study 28928190 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 280
Study 26008653 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided technique
Number of subjects: 200
Study 26008653 — intervention group
Group type: COMPARATOR
Intervention: Land-mark technique
Number of subjects: 200
Study 23159302 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute educational program
Number of subjects: 877
Study 23159302 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 877
Study 21728389 — intervention group
Group type: EXPERIMENTAL
Intervention: ELIOT (21 Gy single dose)
Number of subjects: 178
Study 21728389 — intervention group
Group type: COMPARATOR
Intervention: EBRT (50 Gy whole breast + 10 Gy boost)
Number of subjects: 178
Study 19819114 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (1‐4 mg/d)
Number of subjects: 498
Study 19819114 — intervention group
Group type: EXPERIMENTAL
Intervention: amisulpride (200‐800 mg/d)
Number of subjects: 498
Study 19819114 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine (5‐20 mg/d)
Number of subjects: 498
Study 19819114 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (200‐750 mg/d)
Number of subjects: 498
Study 19819114 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone (40‐160 mg/d)
Number of subjects: 498
Study 16414127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal flap sealing over the operation site
Number of subjects: 39
Study 16414127 — intervention group
Group type: COMPARATOR
Intervention: Control group (operation site left uncovered)
Number of subjects: 39
Study 12782919 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intestinal levodopa infusion
Number of subjects: 12
Study 12782919 — intervention group
Group type: COMPARATOR
Intervention: Oral sustained-release levodopa preparation
Number of subjects: 12
Study 10957888 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 12-hourly for 10 days
Number of subjects: 86
Study 10957888 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 150 mg 12-hourly for 10 days
Number of subjects: 86
Study 10957888 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate 500 mg 6-hourly for 10 days
Number of subjects: 86
Study 9323819 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of tetralogy of Fallot in adulthood
Number of subjects: 104
Study 8406655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention (dietary sodium to 80 mmol/24 h)
Number of subjects: 744
Study 8406655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention
Number of subjects: 744
Study 3535741 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (450 mg/m2)
Number of subjects: 75
Study 3535741 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75
Study 30053397 — intervention group
Group type: EXPERIMENTAL
Intervention: ThuFLEP
Number of subjects: 90
Study 30053397 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 90
Study 30053397 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 90
Study 30053397 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser EEP (HoLEP, ThuFLEP)
Number of subjects: 90
Study 30053397 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stages of training (first 20 surgeries)
Number of subjects: 90
Study 26227799 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 350
Study 26227799 — intervention group
Group type: COMPARATOR
Intervention: amisulpride
Number of subjects: 350
Study 25016533 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy consumption
Number of subjects: 0
Study 25016533 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-related energy expenditure (AREE)
Number of subjects: 0
Study 23095630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunhill (DUN)
Number of subjects: 118
Study 23095630 — intervention group
Group type: COMPARATOR
Intervention: Hemithyroidectomy (HMT)
Number of subjects: 118
Study 19730942 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Xylocaine pump spray plus plain Strepsils
Number of subjects: 191
Study 19730942 — intervention group
Group type: COMPARATOR
Intervention: Strepsils Dual Action anesthetic lozenge plus distilled water spray
Number of subjects: 191
Study 18979599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (n = 44)
Number of subjects: 93
Study 18979599 — intervention group
Group type: COMPARATOR
Intervention: Neutral liquid soap (n = 49)
Number of subjects: 93
Study 15896585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg and propofol 1 mg/kg (group 1 n = 20)
Number of subjects: 40
Study 15896585 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 0.5 mg/kg and propofol 1 mg/kg (group 2 n = 20)
Number of subjects: 40
Study 12169868 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 51
Study 12169868 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 51
Study 12169868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of losartan 25 mg and enalapril 10 mg
Number of subjects: 51
Study 9802752 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 457
Study 9802752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 7715987 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV immunoglobulin (CMVIG) 150 mg/kg
Number of subjects: 183
Study 7715987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 7715987 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV immunoglobulin (CMVIG)
Number of subjects: 183
Study 2692965 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane‐35 for 6 cycles
Number of subjects: 50
Study 2692965 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon for 6 cycles
Number of subjects: 50
Study 879708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thompson endoprosthesis with intensive physical therapy
Number of subjects: 87
Study 879708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thompson endoprosthesis with routine physical therapy
Number of subjects: 87
Study 879708 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with intensive physical therapy
Number of subjects: 87
Study 879708 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation with routine physical therapy
Number of subjects: 87
Study 879708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Thompson endoprosthesis and internal fixation)
Number of subjects: 87
Study 879708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Number of subjects: 87
Study 31227804 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 38
Study 31227804 — intervention group
Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 38
Study 31227804 — intervention group
Group type: COMPARATOR
Intervention: Cocoa butter (CB)
Number of subjects: 38
Study 29778130 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing blood flow rate by 25 rpm for the first two weeks and 50 rpm for the second two weeks during hemodialysis.
Number of subjects: 60
Study 29778130 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard blood flow rate).
Number of subjects: 60
Study 27461166 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 150 mg subcutaneous every 4 weeks
Number of subjects: 410
Study 23838625 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration training (AT) with vibration stimulus (frequency, 40 Hz; amplitude, 2-4 mm)
Number of subjects: 18
Study 23838625 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) without vibration stimulus
Number of subjects: 18
Study 23838625 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration training (AT)
Number of subjects: 18
Study 23838625 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 18
Study 22070452 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist supportive care plus usual care
Number of subjects: 0
Study 22070452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19674354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline solution and salbutamol
Number of subjects: 93
Study 19674354 — intervention group
Group type: COMPARATOR
Intervention: Control group (4.0 mL normal (0.9%) saline with 2.5 mg salbutamol)
Number of subjects: 93
Study 17510676 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐enriched 6% CHO drink
Number of subjects: 29
Study 17510676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15687232 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by purged autologous stem-cell transplantation
Number of subjects: 172
Study 15687232 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and interferon (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon)
Number of subjects: 172
Study 12297768 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-occluded endoscopic injection sclerotherapy (BO-EIS)
Number of subjects: 20
Study 12297768 — intervention group
Group type: COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration (B-RTO)
Number of subjects: 20
Study 10595697 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 392
Study 10595697 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin standard
Number of subjects: 392
Study 10595697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 10595697 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS and Doxazosin standard
Number of subjects: 392
Study 8758250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFO) administered as 6-9 g/m2 over 15 days, repeated every 3 weeks for up to 16 courses, either as a continuous 72 h infusion or as three bolus doses of 3 g/m2 on consecutive days.
Number of subjects: 15
Study 8758250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFO) administration with changes in metabolism measured during early and late courses.
Number of subjects: 15
Study 1883969 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (100 U/kg thrice weekly for 6 weeks, then 50 to 150 U/kg thrice weekly for 6 weeks)
Number of subjects: 131
Study 1883969 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta after crossover from placebo
Number of subjects: 131
Study 1883969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 7037302 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic turning every 2 hours for the first 24 hours post-surgery
Number of subjects: 35
Study 7037302 — intervention group
Group type: COMPARATOR
Intervention: Supine position for the first 24 hours post-surgery
Number of subjects: 35
Study 31770245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise without behavioral approach (NSE)
Number of subjects: 188
Study 31770245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioral approach (NSEB)
Number of subjects: 188
Study 31770245 — intervention group
Group type: COMPARATOR
Intervention: Physical activity prescription (PPA)
Number of subjects: 188
Study 28887907 — intervention group
Group type: EXPERIMENTAL
Intervention: WBB beverage (25 g freeze dried WBB powder)
Number of subjects: 0
Study 28887907 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 26475662 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise rehabilitation (12-month intervention, twice a week, 60 minutes each session)
Number of subjects: 120
Study 26475662 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control group)
Number of subjects: 120
Study 24106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg q.d. for 12 weeks
Number of subjects: 936
Study 24106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 936
Study 24106924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study 22249353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment strategy using the Multiplate analyzer
Number of subjects: 192
Study 22249353 — intervention group
Group type: COMPARATOR
Intervention: Standard administration of 75 mg clopidogrel
Number of subjects: 192
Study 22249353 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplate‐tailored therapy
Number of subjects: 192
Study 19781899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose-based enteral formula (IF)
Number of subjects: 8
Study 19781899 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding formula (SF)
Number of subjects: 8
Study 18046053 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull energy drink (2 mg/kg body mass of caffeine)
Number of subjects: 15
Study 18046053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isoenergetic, isovolumetric, noncaffeinated)
Number of subjects: 15
Study 16128596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 90
Study 16128596 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 90
Study 11911517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with bipolar interferential current (Group A)
Number of subjects: 30
Study 11911517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with low-frequency current (Group B)
Number of subjects: 30
Study 11911517 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 30
Study 11911517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stimulation groups (A and B)
Number of subjects: 30
Study 10194083 — intervention group
Group type: EXPERIMENTAL
Intervention: D0870 (azole)
Number of subjects: 114
Study 8789567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.2 g alcohol.kg‐1 body mass)
Number of subjects: 8
Study 8789567 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 2303280 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (125 mg p.o.)
Number of subjects: 8
Study 2303280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6803692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day for 4 months)
Number of subjects: 17
Study 6803692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 months after bromocriptine)
Number of subjects: 17
Study 6803692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 17
Study 6803692 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine and Placebo
Number of subjects: 17
Study 31288354 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 30 seconds
Number of subjects: 400